Royal Philips announced on Tuesday that it received FDA clearance to market its IntelliSpace Portal 9.0 platform and new applications for neurology, cardiology and oncology.

The platform provides clinicians with a comprehensive overview of each patient. The multimodality clinical applications are optimized to evaluate patients over longer periods of time and help quantify and diagnose conditions.

“Analytics applications optimized for clinical decision support and longitudinal and quantified patient tracking are becoming increasingly important to radiologists,” Mark van Buchem of the Leiden University Medical Center and one of the development partners of the platform, said in a statement.
With cancer and chronic diseases like cardiovascular disease, COPD and dementia becoming more prevalent in the U.S., timely diagnosis and early intervention is more important than ever.

These conditions also require long-term treatment and continuous follow-up to monitor the patient's response to therapy and help clinicians determine the next steps to take.

One of the new applications for the platform is called Longitudinal Brain Imaging (LoBI). It analyzes brain images and evaluates neurological disorders over time to help clinicians monitor disease progression in patients with neurodegenerative disorders.

The new quantitative European Association for the Study of the Liver (qEASL) technology enhances the measurement of tumor volume based on MR and CT scans. It provides a visual depiction of how cells respond to therapy.

The Lung Nodule Assessment application provides quantitative and characterization information about nodules in the lung in a single CT study or during the course of multiple thoracic studies.

Philips first introduced the IntelliSpace Portal 9.0, which was available in countries outside the U.S. at the time, at the 2016 Radiological Society of North American annual meeting.

Cardiology Homepage